Urgency of Hep C Treatment Rises as Fibrosis Advances

November 25, 2015 The level of fibrosis (liver scarring) among people with hepatitis C virus (HCV) strongly predicts their risk of developing serious liver disease or dying within five years, aidsmap reports. Publishing their findings in Clinical Infectious Diseases, researchers from the Chronic Hepatitis Cohort Study (CHeCS) examined the rates…

Read More

Good Results for Sovaldi and Ravidasvir Treating Hep C Genotype 4

November 24, 2015 Twelve or 16 weeks of Gilead Sciences’ Sovaldi (sofosbuvir) and Pharco Pharmaceuticals’ investigational ravidasvir cured high rates of people with genotype 4 of hepatitis C virus (HCV) in a recent large trial, MedPage Today reports. The Phase III PYRAMID trial included 300 people with genotype 4 treated…

Read More

More Good Hep C Cure Rates for Sovaldi/Velpatasvir

November 24, 2015 Gilead Sciences’ fixed-dose combination tablet of Sovaldi (sofosbuvir) and the investigational pangenotypic NS5A inhibitor velpatasvir, with or without ribavirin, yielded good results among a cohort of people with various genotypes of hepatitis C virus (HCV) and decompensated cirrhosis, MedPage Today reports. Researchers from the Phase III open-label…

Read More

8 Weeks of Harvoni + Vedroprevir Cures 96% of Hard-to-Treat Hep C

November 23, 2015 An eight-week regimen of Gilead Sciences’ Harvoni (ledipasvir/sofosbuvir) plus its investigational vedroprevir boasted a near-perfect cure rate among those with genotype 1 and advanced liver disease, Medpage Today reports. Researchers conducted a single-center, open-label study of Harvoni plus the NS3/4A protease inhibitor vedroprevir, with or without ribavirin,…

Read More

People With Hep B Have Raised Risk of Only Liver Cancer

November 23, 2015 Hepatitis B virus (HBV) raises the risk of liver cancer, but not non-Hodgkin lymphoma, pancreatic cancer or cancer in general. Publishing their findings in the Journal of Viral Hepatology, researchers compared cancer rates between a nationwide Danish cohort of 4,345 people diagnosed with hep B between 1976…

Read More

High Genotype 2 and 3 Hep C Cure Rates for New AbbVie Combo

November 19, 2015 AbbVie’s investigational hepatitis C virus (HCV) treatments ABT-493 and ABT-530, with and without ribavirin, posted mostly high cure rates among people with genotypes 2 and 3 of the virus. Researchers in the ongoing Phase II, two-part SURVEYOR-II study are testing eight- and 12-week regimens of the NS3/4A…

Read More

Hepatitis C Cure Often Leads to Improvement in Liver Health

November 20, 2015 Individuals with advanced fibrosis or cirrhosis who are cured of hepatitis C virus (HCV) often experience regression of liver damage, improving by at least one fibrosis score, HIVandHepatitis.com reports. Researchers conducted a retrospective chart review of data from 100 people with such advanced liver damage—35 had advanced…

Read More

Promising Results for REP 2139 Treating Hep B and D Coinfection

November 18, 2015 A nucleic acid-based polymer called REP 2139, given alone and with interferon, has shown promise treating coinfection with hepatitis B virus (HBV) and hepatitis delta virus (HDV), HIVandHepatitis.com reports. Researchers in the Phase II trial treated 12 HBV/HDV-coinfected participants who had a baseline serum hep B surface…

Read More

Excellent Real-World Results for 8 Weeks of Hep C Treatment Harvoni

November 18, 2015 An eight-week treatment of Gilead Sciences’ hepatitis C virus (HCV) treatment Harvoni (ledipasvir/sofosbuvir) has demonstrated excellent results in a real-world trial, aidsmap reports. Researchers reported an analysis of an eight-week Harvoni regimen given to 148 participants in the German real-world GECCO cohort. Results were presented at the…

Read More

Today’s Hep C Drugs May Avert Many Liver Transplants

November 18, 2015 The high success rate of today’s hepatitis C virus (HCV) treatments may keep many people from ultimately needing a liver transplant, freeing up available livers for others who require them. Researchers analyzed data from five clinical trials of the most recent generation of direct-acting antivirals for hep…

Read More